

**Credit Suisse International** 

## AMENDMENT TO PROGRAM INFORMATION

Type of Information: Amendment to Program Information Date of Announcement: 19 April 2022 Issuer Name: Credit Suisse International **David Mathers** Name and Title of Representative: Chief Executive Officer Address of Head Office: One Cabot Square, London E14 4QJ, UK +44 (0)20 7888 8888 Telephone: Contact Person: Attorney-in-Fact: Eiichi Kanda, Attorney-at-law Chihiro Ashizawa, Attorney-at-law Yasuaki Dote, Attorney-at-law Tomoki Goto, Attorney-at-law Clifford Chance (Gaikokuho Kyodo Jigyo) Palace Building, 3rd floor 1-1, Marunouchi 1-chome Chiyoda-ku, Tokyo 100-0005 Telephone: 81-3-6632-6600 Address of Website for Announcement: https://www.jpx.co.jp/english/equities/products/tpbm/announc ement/index.html Information on initial Program Information: Date of Announcement: 23 April 2021 Scheduled Issuance Period: 27 April 2021 to 26 April 2022 Maximum Outstanding Issuance Amount: Unlimited

This amendment is filed to update the information included in the Program Information dated 23 April 2021 (as amended on 2 June 2021, 30 July 2021, 22 September 2021 and 17 February 2022). This constitutes an integral part of the Program Information dated 23 April 2021 (as amended on 2 June 2021, 30 July 2021, 22 September 2021 and 17 February 2022) and shall be read together with it.



# **Credit Suisse International**

Unlisted Securities Programme (Unlimited Program Size)

This Supplement (the "Supplement") is supplemental to, and should be read in conjunction with, (i) the Listing Supplement dated 26 April 2018 (the "Listing Supplement") in respect of the unlisted securities programme (the "Programme") established by Credit Suisse International ("CSi" or the "Issuer") on 17 June 2011 for the issuance of notes (the "Notes") of CSi and Credit Suisse AG ("CS"), (ii) any other documents incorporated by reference therein and (iii) in relation to any particular Notes, the Pricing Supplement relating to those Notes. Capitalised terms used in this Supplement but not defined herein shall have the meanings ascribed to them in the Listing Supplement.

Supplement to Listing Supplement dated 19 April 2022

#### **CREDIT SUISSE INTERNATIONAL**

The section in the Listing Supplement entitled "Change", "Names and Addresses of Directors and Executives" and "Legal and Arbitration Proceedings" shall be replaced with the information below.

#### Change

Apart from (1) the uncertainty relating to the impact of the ongoing global COVID-19 pandemic disclosed in (i) the CSi Registration Document (as supplemented, the same hereinafter in this "Credit Suisse International" section), including in "Risk Factors—3. Market risk—3.1 The ongoing global COVID-19 pandemic has adversely affected, and may continue to adversely affect, CSi's business, operations and financial performance", (ii) the sections of the 2020 CSi Annual Report headed "Strategic Report—Credit Suisse International at a glance—Operating environment" (on pages 12 to 16), "Strategic Report-Performance" (on pages 17 to 22), "Strategic Report-Principal risks and uncertainties" (on pages 23 to 26), and "Financial Statements-Note 45 Financial Risk Management" (on pages 188 to 206), (iii) the sections of the Form 20-F Dated 18 March 2021 (as defined in the CSi Registration Document, the same hereinafter) headed "II-Operating and financial review—Operating environment" on pages 60 to 62, "II—Operating and financial review—Credit Suisse—COVID-19 pandemic and related regulatory measures" on pages 68 to 69 and "III-Treasury, Risk, Balance sheet and Off-balance sheet-Risk management—Key risk developments" on pages 139 to 141, (iv) the sections of the 2021 CSi H1 Interim Report (as defined in the CSi Registration Document) headed "Credit Suisse International at a glance—Operating environment" on pages 4 to 7, "Performance" on pages 8 to 12 and "Principal risks and uncertainties—Principal risks—Other key risks—COVID-19" on page 14, (v) the sections of the Form 6-K Dated 4 November 2021 headed "I-Credit Suisse results-Operating environment" on pages 4 to 5, "I-Credit Suisse results-Credit Suisse-Other information—COVID-19 pandemic" on page 16, and "II—Treasury, risk, balance sheet and offbalance sheet—Risk Management—Key risk developments—COVID-19 pandemic" on page 65 and (vi) the section of the Form 6-K Dated 10 February 2022 (as defined in the CSi Registration Document) headed "Credit Suisse—Other information—COVID-19 pandemic" on page 13 and (2) the consequences of the matters disclosed in (i) the CSi Registration Document, in "Risk Factors-2. Credit risk—2.3 Significant negative consequences of the supply chain finance funds and USbased hedge fund matters", (ii) the sections of the 2020 CSi Annual Report headed "Strategic Report—Credit Suisse International at a glance—Operating environment" on pages 12 to 16, "Strategic Report—Performance" on pages 17 to 22, "Principal risks and uncertainties" on pages 23 to 26, "Strategic Report—Directors' Report—Subsequent events", and "Financial Statements— Note 49 Subsequent Events" on page 216, (iii) the sections of the 2021 CSi H1 Interim Report headed "Credit Suisse International at a glance—Operating environment" on pages 4 to 7, "Performance" on pages 8 to 12 and "Principal risks and uncertainties—Principal risks—Other key risks—Archegos" on page 14, (iv) the sections of the Form 6-K Dated 4 November 2021 headed "I—Credit Suisse results—Credit Suisse—Other information—Mozambique Matter" on pages 14 to 15, "I—Credit Suisse results—Credit Suisse—Other information—Archegos Capital Management" on page 15, "I—Credit Suisse results—Credit Suisse—Other information—Supply chain finance funds matter" on pages 15 to 16 and "I-Credit Suisse results-Credit Suisse-Other information—Significant negative consequences of the supply chain finance funds and Archegos matters" on page 16, "II—Treasury, risk, balance sheet and off-balance sheet—Risk Management—Key risk developments—Archegos and supply chain finance funds matters" on page 64 and "III—Condensed consolidated financial statements—unaudited—Notes to the condensed consolidated financial statements—unaudited—Note 3 Business developments and subsequent events—Business developments—Archegos Capital Management" on page 90 and "III—Condensed consolidated financial statements—unaudited—Notes to the condensed consolidated financial statements—unaudited—Note 3 Business developments and subsequent

events—Business developments—Supply chain finance funds matter" on page 90, (v) the sections of the Form 6-K Dated 10 February 2022 headed "Credit Suisse—2021 results" on page 4 and "Credit Suisse—Other information—Supply chain finance funds matter" and "Credit Suisse—Other information—Significant negative consequences of the supply chain finance funds and Archegos matters" on page 12 and (vi) as more fully described in the exhibit (Credit Suisse Earnings Release 4Q21) to the Form 6-K Dated 10 February 2022, the net loss that Credit Suisse reported in the fourth quarter of 2021, there has been no significant change in the financial performance of CSi since 30 June 2021.

Apart from (1) the uncertainty relating to the impact of the ongoing global COVID-19 pandemic disclosed in (i) the CSi Registration Document, including in "Risk Factors—3. Market risk—3.1 The ongoing global COVID-19 pandemic has adversely affected, and may continue to adversely affect, CSi's business, operations and financial performance", (ii) the sections of the 2020 CSi Annual Report headed "Strategic Report—Credit Suisse International at a glance—Operating environment" (on pages 12 to 16), "Strategic Report—Performance" (on pages 17 to 22), "Strategic Report—Principal risks and uncertainties" (on pages 23 to 26), and "Financial Statements—Note 45 Financial Risk Management" (on pages 188 to 206), (iii) the sections of the Form 20-F Dated 18 March 2021 headed "II-Operating and financial review-Operating environment" on pages 60 to 62, "II—Operating and financial review—Credit Suisse—COVID-19 pandemic and related regulatory measures" on pages 68 to 69 and "III—Treasury, Risk, Balance sheet and Off-balance sheet—Risk management—Key risk developments" on pages 139 to 141, (iv) the sections of the 2021 CSi H1 Interim Report headed "Credit Suisse International at a glance—Operating environment" on pages 4 to 7, "Performance" on pages 8 to 12 and "Principal risks and uncertainties—Principal risks—Other key risks—COVID-19" on page 14, (v) the sections of the Form 6-K Dated 4 November 2021 headed "I—Credit Suisse results—Operating environment" on pages 4 to 5, "I-Credit Suisse results-Credit Suisse-Other information-COVID-19 pandemic" on page 16, and "II—Treasury, risk, balance sheet and off-balance sheet— Risk Management—Key risk developments—COVID-19 pandemic" on page 65 and (vi) the section of the Form 6-K Dated 10 February 2022 headed "Credit Suisse-Other information-COVID-19 pandemic" on page 13 and (2) the consequences of the matters disclosed in (i) the CSi Registration Document, in "Risk Factors—2. Credit risk—2.3 Significant negative consequences of the supply chain finance funds and US-based hedge fund matters", (ii) the sections of the 2020 CSi Annual Report headed "Strategic Report—Credit Suisse International at a glance—Operating environment" on pages 12 to 16, "Strategic Report—Performance" on pages 17 to 22, "Principal risks and uncertainties" on pages 23 to 26, "Strategic Report—Directors' Report—Subsequent events" (on page 51), and "Financial Statements—Note 49 Subsequent Events" on page 216, (iii) the sections of the 2021 CSi H1 Interim Report headed "Credit Suisse International at a glance— Operating environment" on pages 4 to 7, "Performance" on pages 8 to 12 and "Principal risks and uncertainties—Principal risks—Other key risks—Archegos" on page 14, (iv) the sections of the Form 6-K Dated 4 November 2021 headed "I-Credit Suisse results-Credit Suisse-Other information—Mozambique Matter" on pages 14 to 15, "I—Credit Suisse results—Credit Suisse— Other information—Archegos Capital Management" on page 15, "I—Credit Suisse results—Credit Suisse—Other information—Supply chain finance funds matter" on pages 15 to 16 and "I—Credit Suisse results—Credit Suisse—Other information—Significant negative consequences of the supply chain finance funds and Archegos matters" on page 16, "II-Treasury, risk, balance sheet and off-balance sheet—Risk Management—Key risk developments—Archegos and supply chain finance funds matters" on page 64 and "III-Condensed consolidated financial statementsunaudited—Notes to the condensed consolidated financial statements—unaudited—Note 3 Business developments and subsequent events—Business developments—Archegos Capital Management" on page 90 and "III—Condensed consolidated financial statements—unauditedNotes to the condensed consolidated financial statements—unaudited—Note 3 Business developments and subsequent events—Business developments—Supply chain finance funds matter" on page 90, (v) the sections of the Form 6-K Dated 10 February 2022 headed "Credit Suisse—2021 results" on page 4, "Credit Suisse—Other information—Supply chain finance funds matter" and "Credit Suisse—Other information—Significant negative consequences of the supply chain finance funds and Archegos matters" on page 12 and (vi) as more fully described in the exhibit (Credit Suisse Earnings Release 4Q21) to the Form 6-K Dated 10 February 2022, the net loss that Credit Suisse reported in the fourth quarter of 2021, there has been no significant change in the financial position of CSi since 30 June 2021.

Apart from (1) the uncertainty relating to the impact of the ongoing global COVID-19 pandemic disclosed in (i) the CSi Registration Document, including in "Risk Factors—3. Market risk—3.1 The ongoing global COVID-19 pandemic has adversely affected, and may continue to adversely affect, CSi's business, operations and financial performance", (ii) the sections of the 2020 CSi Annual Report headed "Strategic Report—Credit Suisse International at a glance—Operating environment", "Strategic Report—Performance" (on pages 17 to 22), "Strategic Report—Principal risks and uncertainties" (on pages 23 to 26), and "Financial Statements-Note 45 Financial Risk Management" (on pages 188 to 206), (iii) the sections of the Form 20-F Dated 18 March 2021 headed "II—Operating and financial review—Operating environment" on pages 60 to 62, "II— Operating and financial review—Credit Suisse—COVID-19 pandemic and related regulatory measures" on pages 68 to 69 and "III-Treasury, Risk, Balance sheet and Off-balance sheet-Risk management—Key risk developments" on pages 139 to 141, (iv) the sections of the 2021 CSi H1 Interim Report headed "Credit Suisse International at a glance—Operating environment" on pages 4 to 7, "Performance" on pages 8 to 12 and "Principal risks and uncertainties—Principal risks-Other key risks-COVID-19" on page 14, (v) the sections of the Form 6-K Dated 4 November 2021 headed "I—Credit Suisse results—Operating environment" on pages 4 to 5, "I— Credit Suisse results—Credit Suisse—Other information—COVID-19 pandemic" on page 16, and "II—Treasury, risk, balance sheet and off-balance sheet—Risk Management—Key risk developments—COVID-19 pandemic" on page 63 and (vi) the section of the Form 6-K Dated 10 February 2022 headed "Credit Suisse—Other information—COVID-19 pandemic" on page 13 and (2) the consequences of the matters disclosed in (i) the CSi Registration Document, in "Risk Factors—2. Credit risk—2.3 Significant negative consequences of the supply chain finance funds and US-based hedge fund matters", (ii) the sections of the 2020 CSi Annual Report headed "Strategic Report—Credit Suisse International at a glance—Operating environment" on pages 12 to 16, "Strategic Report—Performance" on pages 17 to 22, "Principal risks and uncertainties" on pages 23 to 26, "Strategic Report—Directors' Report—Subsequent events" (on page 51), and "Financial Statements—Note 49 Subsequent Events" on page 216, (iii) the sections of the 2021 CSi H1 Interim Report headed "Credit Suisse International at a glance—Operating environment" on pages 4 to 7, "Performance" on pages 8 to 12 and "Principal risks and uncertainties—Principal risks—Other key risks—Archegos" on page 14, (iv) the sections of the Form 6-K Dated 4 November headed "I—Credit Suisse results—Credit Suisse—Other information—Mozambique Matter" on pages 14 to 15, "I-Credit Suisse results-Credit Suisse-Other information-Archegos Capital Management" on page 15, "I-Credit Suisse results-Credit Suisse-Other information—Supply chain finance funds matter" on pages 15 to 16 and "I—Credit Suisse results—Credit Suisse—Other information—Significant negative consequences of the supply chain finance funds and Archegos matters" on page 16, "II-Treasury, risk, balance sheet and offbalance sheet—Risk Management—Key risk developments—Archegos and supply chain finance funds matters" on page 64 and "III—Condensed consolidated financial statements – unaudited— Notes to the condensed consolidated financial statements—unaudited—Note 3 Business developments and subsequent events—Business developments—Archegos Capital Management" on page 90 and "III—Condensed consolidated financial statements—unaudited—Notes to the condensed consolidated financial statements—unaudited—Note 3 Business developments and subsequent events—Business developments—Supply chain finance funds matter" on page 90 and (v) the sections of the Form 6-K Dated 10 February 2022 headed "Credit Suisse—2021 results" on page 4 and "Credit Suisse—Other information—Supply chain finance funds matter" and "Credit Suisse—Other information—Significant negative consequences of the supply chain finance funds and Archegos matters" on page 12, there has been no material adverse change in the prospects of CSi since 31 December 2020.

## Names and Addresses of Directors and Executives

The business address of the members of the Board of Directors is One Cabot Square, London E14 4QJ.

Ms. Clare Brady ceased to be a Director of CSi with effective date 31 December 2021.

Accordingly, the current members of the Board of Directors, their role within the Issuer and their principal activities outside the Issuer, if any, are as follows:

Board Member	External Activities
John Devine (Chair and Independent Non- Executive)	<ul> <li>Independent member and Chair of the Board of Directors, Chair of the Nomination Committee, Interim Chair of the Advisory Remuneration Committee, Member of the Risk Committee, and Member of the Conflicts Committee of the Issuer and Credit Suisse Securities (Europe) Limited.</li> </ul>
	<ul> <li>Mr. Devine is also</li> <li>Non-Executive Director, Chair of Audit Committee, Member of Risk Committee, and Remuneration Committee and Member of Nominations Committee of Standard Life Aberdeen PLC; and</li> <li>Non-Executive Director, Chair of Audit Committee, Member of Risk Committee and Nominations Committee of Citco Custody (UK) Ltd and Citco Custody Holding Ltd Malta.</li> </ul>
Christopher Horne (Deputy CEO)	<ul> <li>Managing Director in Credit Suisse and Chair of the Disclosure Committee of the Issuer.</li> <li>Mr. Horne is also Deputy CEO of the Issuer and Credit Suisse Securities (Europe) Ltd.</li> <li>Member of the Board of Directors of the Issuer, Credit Suisse Securities (Europe) Limited, Credit Suisse Investment Holdings (UK) and Credit Suisse Investments (UK), Branch Manager and Chair of the Management Committee of Credit Suisse AG, London Branch.</li> </ul>
David Mathers – Chief Executive Officer (CEO)	<ul> <li>Managing Director in the CFO division of Credit Suisse AG,</li> <li>Mr. Mathers is also CEO of the Issuer and Credit Suisse Securities (Europe) Limited and CFO of Credit Suisse AG.</li> <li>Member of the Board of Directors of the Issuer and Credit Suisse Securities (Europe) Limited.</li> <li>Member of the Executive Board of Credit Suisse AG and Credit Suisse Group AG.</li> </ul>

	Mr. Mathers is also Chair of Asset Resolution
	Unit of Credit Suisse AG and Credit Suisse Group AG.
Doris Honold (Independent Non-Executive)	<ul> <li>Independent member of the Board of Directors, Chair of the Risk Committee, Member of the Audit Committee, Nomination Committee and Conflicts Committee of the Issuer and Credit Suisse Securities (Europe) Limited.</li> <li>Non-Executive Director of Move Digital AG (Credit Suisse AG affiliate).</li> <li>Ms. Honold is also:         <ul> <li>Non-Executive Director and Chair of Audit and Risk Committee of AION NV/SA;</li> <li>Member of the Advisory Board of Viridios Capital (Bahamas) Ltd;</li> <li>Non-Executive Director of ZOPA Limited; and</li> </ul> </li> </ul>
Caroline Waddington – Chief Financial	<ul> <li>Trustee of the Climate Bonds Initiative.</li> <li>Managing Director in the CFO division of the</li> </ul>
Caroline Waddington – Chief Financial Officer (CFO)  Jonathan Moore	Issuer.  Ms. Waddington is also CFO for Credit Suisse EMEA entities, including the Issuer, and Chair of the UK Pension Committee.  Member of the Board of Directors of the Issuer, Credit Suisse Securities (Europe) Limited, Credit Suisse Investment Holdings (UK) and Credit Suisse Investments (UK) and Member of the Management Committee of Credit Suisse AG, London Branch.  Ms. Waddington is a member of the Board of Directors of:  NameCo (No.357) Limited; and Brook House (Clapham Common) Management Company Limited.  Managing Director in the Investment Bank Division of the Issuer.  Mr. Moore is also Co-Head of Global Credit
	Products, Head of Credit Products in EMEA and Senior Manager for Credit & Clients in the UK.  Member of the Board of Directors of the Issuer and of Credit Suisse Securities (Europe) Limited.
Nicola Kane	<ul> <li>Managing Director in the COO division of the Issuer.</li> <li>Ms. Kane is also Global Head of Group Operations and Co-Head of Operations Technology and Solutions Delivery.</li> <li>Member of the Board of Directors of the Issuer and Credit Suisse Securities (Europe) Limited.</li> </ul>
Debra Jane Davies (Independent Non-Executive)	<ul> <li>Independent member of the Board of Directors, Member of the Audit Committee, Nomination Committee, Conflicts Committee and the Advisory Remuneration Committee of the Issuer and Credit Suisse Securities (Europe) Limited.</li> <li>Ms. Davies is also:         <ul> <li>Non-Executive Director and Member of the Risk Committee, Audit Committee and Remuneration Committee of AXA UK plc; Non-Executive Director of AXA Insurance</li> </ul> </li> </ul>

	UK plc and AXA PPP Healthcare
	Limited.

## Legal and Arbitration Proceedings

During the period of 12 months ending on the date of second supplement of CSi Registration Document, there have been no governmental, legal or arbitration proceedings which may have, or have had in the recent past, significant effects on the financial position or profitability of CSi, and the Issuer is not aware of any such proceedings being either pending or threatened, except as disclosed in (i) the section of the 2020 CSi Annual Report headed "Financial Statements for the year ended 31 December 2020-Notes to the Financial Statements for the year ended 31 December 2020—40 Contingent Liabilities, Guarantees and Commitments" on pages 143 to 144, (ii) the section of the 2021 CSi H1 Interim Report headed "Condensed Consolidated Interim Financial Statements for the six months ended 30 June 2021 (Unaudited)-Notes to the Condensed Consolidated Interim Financial Statements for the Six Months Ended 30 June 2021 (Unaudited)—12 Contingent Liabilities and Commitments" on pages 33 to 34, (iii) the 2020 CS Annual Report under the heading "Litigation" (Note 40 to the Consolidated financial statements of CSG) on pages 400 to 411 of the Form 20-F Dated 18 March 2021, (iv) the section of the Form 6-K Dated 22 April 2021 headed "Credit Suisse-Results details-Litigation" on page 4, (iv) the section of the Form 6-K Dated 6 May 2021 headed "III-Condensed consolidated financial statements-unaudited—Notes to the condensed consolidated financial statements-unaudited— Note 33 Litigation" on pages 142 to 143, (v) the section of the Form 6-K Dated 29 July 2021 headed "Condensed consolidated financial statements-unaudited-Notes to the condensed consolidated financial statements – unaudited—Note 33 Litigation" on pages 150 to 153, (vi) the section of the Form 6-K Dated 4 November 2021 headed "Litigation" (note 33 to the condensed consolidated financial statements of CSG on pages 153 to 155 of the Form 6-K Dated 4 November 2021) and (vii) the section headed "Litigation" on page 5 of the exhibit (Credit Suisse Earnings Release Q421) to the Form 6-K Dated 10 February 2022.

Provision for litigation is disclosed in (i) the section of the 2020 CSi Annual Report headed "Financial Statements for the year ended 31 December 2020—Notes to the Financial Statements for the year ended 31 December 2020—29 Provisions" on pages 108 to 109, and (ii) the section of the 2021 CSi H1 Interim Report headed "Condensed Consolidated Interim Financial Statements for the six months ended 30 June 2021 (Unaudited)—Notes to the Condensed Consolidated Interim Financial Statements for the Six Months Ended 30 June 2021 (Unaudited)—12 Contingent Liabilities and Commitments" on pages 33 to 34.